Thus, we suggest that R-Tf-D-LP4 peptide inhibits steatosis and NASH by increasing fatty acid oxidation via alterations in the liver transcriptional program; thus, it offers a promising therapeutic approach for steatosis and NASH. Here, TF is linked to metabolic dysfunction-associated steatohepatitis.